Roche Pharmaceutical Development and Sales Overview

Kadcyla CER growth -3% Europe +8% Global sales CHFbn CER growth +11% Regional sales 1.8 US 1.6 1.4 1.2 1.0 0.8 0.6 0.4 0.2 0.0 YTD Sep 19 YTD Sep 20 YTD Sep 21 YTD Sep 22 YTD Sep 2022 sales of CHF 1,590m • US: Growth in adjuvant eBC; share decline in metastatic BC due to competition • . EU: Strong uptake in adjuvant eBC in patients with residual disease after neoadjuvant treatment International: Growth driven by all regions (LATAM, EEMEA, APAC) CER=Constant Exchange Rates Japan +21% International +50% Roche 160

View entire presentation